Montelukast treats asthma in patients 12 months and older. Prevents exercise-induced bronchoconstriction in patients 6 years and older. Relieves seasonal allergic rhinitis symptoms in patients 2 years and older
Montelukast may cause serious mental health changes during or after treatment. Immediate medical attention needed for symptoms like agitation, hallucinations, or suicidal thoughts. Should not be used to treat sudden asthma attacks
FDA has issued a boxed warning for serious neuropsychiatric events. Montelukast is a selective leukotriene receptor antagonist. Approved for asthma prevention and chronic treatment. Available in tablet, chewable tablet, and granule forms
Treats asthma and prevents exercise-induced asthma symptoms. Blocks leukotrienes causing inflammation and swelling. Available in 4mg, 5mg chewable tablets, 4mg granules, and 10mg tablets
Cetcip L contains Levocetirizine and Montelukast for allergy management. Levocetirizine reduces allergy symptoms like itching and swelling. Montelukast blocks leukotrienes and prevents asthma attacks
Manufactured by Systopic Laboratories Pvt Ltd. Contains Montelukast and Fexofenadine as active ingredients. No prescription required